Maxcyte (MXCT) experienced a negative impact on its stock following the release of the Q1 2024 EPS surprise. Despite a positive EPS surprise of $0.04, the stock price declined by 10.85%1. This suggests that the market may have had concerns or reacted negatively to other aspects of the earnings report, such as lower revenue or guidance, or may have had broader market or sector-specific factors at play.
MXCT Percentage Change, EPS Surprise